Thyroid cancer affects people of all ages, and its patterns differ by histology. Differentiated cancers make up over 85% of cases, while anaplastic thyroid cancer accounts for about 1%. Incidental detection from thyroid nodules is common in population data, and prior head-and-neck radiation can raise risk 7–10 times. This page also looks at global deaths, and how diagnosis timing and follow-up decisions influence costs and outcomes.
Key Takeaways
- Thyroid cancer incidence increased by about 3% per year in the US from 2011 to 2016 (SEER trend reported by NCI)
- More than 80% of thyroid cancer cases are diagnosed after incidental detection of thyroid nodules (incidental diagnoses dominate in population-level data)
- In the United States, the median time from abnormal ultrasound to diagnosis of thyroid cancer is reported as ~30 days in clinical workflow studies (varies by system)
- Thyroid cancer is 7–10 times more likely in people who have undergone prior radiation exposure to the head and neck than in the general population
- Over 85% of thyroid cancers are differentiated thyroid cancers (papillary and follicular)
- Anaplastic thyroid cancer accounts for about 1% of thyroid cancers
- Global thyroid cancer burden is estimated at about 43,800 deaths in 2020 (GLOBOCAN 2020)
- US healthcare expenditures attributable to thyroid cancer are in the billions of dollars annually in national cost analyses (SEER-Medicare/claims-based estimates summarized in peer-reviewed work)
- In an analysis of US patients, total costs of thyroid cancer increased substantially after diagnosis (mean costs over follow-up reported in claims study)
Thyroid cancer incidence is rising, mostly detected incidentally, with growing costs and strongly varied outcomes by risk.
Related reading
01 · Category
Screening & Care Pathways11 stats
01
Thyroid cancer incidence increased by about 3% per year in the US from 2011 to 2016 (SEER trend reported by NCI)
02
More than 80% of thyroid cancer cases are diagnosed after incidental detection of thyroid nodules (incidental diagnoses dominate in population-level data)
03
In the United States, the median time from abnormal ultrasound to diagnosis of thyroid cancer is reported as ~30 days in clinical workflow studies (varies by system)
04
Approximately 50–60% of patients with low-risk papillary microcarcinoma on active surveillance do not require surgery during follow-up (proportion remaining on surveillance varies by study)
05
In differentiated thyroid cancer, radioactive iodine (RAI) is used in selected patients; guidelines commonly consider RAI for intermediate- and high-risk disease (risk-stratified use)
06
Fine-needle aspiration (FNA) is recommended for thyroid nodules based on ultrasound pattern and size thresholds (FNA criteria are explicitly specified in the ATA guideline document)
07
The Bethesda System uses 6 diagnostic categories for thyroid cytology, defining different implied malignancy risks and management pathways
08
Thyroid cancer is among cancers with widespread use of Tg (thyroglobulin) and neck ultrasound for surveillance in differentiated disease (monitoring framework reported in guidelines)
09
2.3% of individuals with thyroid nodules underwent thyroid cancer diagnosis within 1 year (incident-detection style timeframe)
10
0.9% of individuals with thyroid nodules underwent thyroid cancer diagnosis within 6 months (incident-detection style timeframe)
11
4.6% of individuals with thyroid nodules underwent thyroid cancer diagnosis within 2 years (incident-detection style timeframe)
Interpretation
Screening & Care Pathways Interpretation
Across the screening and care pathways for thyroid cancer, the rise in incidence of about 3% per year from 2011 to 2016 in the US alongside the fact that over 80% of cases are found incidentally from nodules suggests much of the growth is being driven by how often nodules are detected and worked up, with clinical timelines showing diagnosis can occur in roughly 30 days and many low risk microcarcinomas avoiding surgery on active surveillance.
report visual · Comparison
Near-term thyroid cancer diagnosis after thyroid nodules (incident-detection share)
Among individuals with thyroid nodules in the United States, the share who receive a thyroid cancer diagnosis rises over time—peaking at 2 years—so the 2-year leader is higher than
4.6% of individuals with thyroid nodules underwent thyroid cancer diagnosis within 2 years (incident-detection style tim4.6%
2.3% of individuals with thyroid nodules underwent thyroid cancer diagnosis within 1 year (incident-detection style time
2.3%
0.9% of individuals with thyroid nodules underwent thyroid cancer diagnosis within 6 months (incident-detection style ti
0.9%
source-verifiedpmc.ncbi.nlm.nih.gov
02 · Category
Risk Factors & Biology8 stats
01
Thyroid cancer is 7–10 times more likely in people who have undergone prior radiation exposure to the head and neck than in the general population
02
Over 85% of thyroid cancers are differentiated thyroid cancers (papillary and follicular)
03
Anaplastic thyroid cancer accounts for about 1% of thyroid cancers
04
Thyroid cancers are about 3–4 times more common in women than in men for differentiated histologies (papillary/follicular)
05
PTC is characterized by BRAF V600E and RET/PTC rearrangements; BRAF V600E is present in ~45% of papillary thyroid cancers (meta-analysis estimate varies by cohort)
06
RET mutations/rearrangements are present in a substantial fraction of papillary thyroid cancers; RET/PTC rearrangements occur in about 10–20% (cohort estimates vary)
07
About 30% of differentiated thyroid cancers harbor actionable alterations such as BRAF V600E or RET fusion (molecular profiling aggregates)
08
In patients with differentiated thyroid cancer treated with radioactive iodine, about 10–15% develop radioiodine-refractory disease
Interpretation
Risk Factors & Biology Interpretation
In the Risk Factors and Biology view of thyroid cancer, prior head and neck radiation raises risk 7 to 10 times while biology is dominated by differentiated tumors, which make up over 85%, and their common molecular drivers such as BRAF V600E in about 45% of papillary cancers and RET/PTC rearrangements in roughly 10 to 20% help explain both the strong female bias and the overall patterns seen in the disease.
More related reading
03 · Category
Market, Costs & Drugs5 stats
01
Global thyroid cancer burden is estimated at about 43,800 deaths in 2020 (GLOBOCAN 2020)
02
US healthcare expenditures attributable to thyroid cancer are in the billions of dollars annually in national cost analyses (SEER-Medicare/claims-based estimates summarized in peer-reviewed work)
03
In an analysis of US patients, total costs of thyroid cancer increased substantially after diagnosis (mean costs over follow-up reported in claims study)
04
In radioiodine-treated differentiated thyroid cancer, annual follow-up costs vary; published estimates for monitoring (ultrasound, TSH, Tg testing) show multi-hundred-dollar per-year ranges
05
Levemir? (N/A)
Interpretation
Market, Costs & Drugs Interpretation
With thyroid cancer linked to about 43,800 deaths globally in 2020 and running into billions of dollars in annual US healthcare costs, the data suggest that from market and drug related perspectives the financial burden is substantial and likely rises after diagnosis, underscoring why monitoring and ongoing treatment resources remain a major cost driver.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Thyroid Cancer Statistics. Gitnux. https://gitnux.org/thyroid-cancer-statistics
MLA
Stefan Wendt. "Thyroid Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/thyroid-cancer-statistics.
Chicago
Stefan Wendt. 2026. "Thyroid Cancer Statistics." Gitnux. https://gitnux.org/thyroid-cancer-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)